http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020281976-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f47c750954e13a1ed0be96c1bf1c51c7
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0025
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
filingDate 2018-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b110fb0ec7adb4683889716b0aa08132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bd067f60971be171d670179b519c4a6
publicationDate 2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2020281976-A1
titleOfInvention Prevention and treatment of gvhd and autoimmune diseases
abstract Disclosed herein are methods of preventing and treating GVHD and autoimmune diseases. The methods entail administering one or more doses of an effective amount of a therapeutic agent to a subject to in vivo knock down Stat3 in the T cells and/or B cells of the subject. Alternatively, the methods entail contacting donor T cells and/or B cells with an effective amount of a therapeutic agent to in vitro knock down Stat3 and administering the Stat3-deficient T cells and/or B cells to the subject. Some examples of the therapeutic agent include small molecule Stat3 inhibitors such as Stat3 siRNAs delivered by an antibody to specifically knock down Stat3 in the lymphocytes of the target tissue.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11434291-B2
priorityDate 2017-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018142261-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015120436-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013052731-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7098192-B2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394205
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6331297
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395300
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395298
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394204
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394386
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398978
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416078
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91670
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4929
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID320930
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16759173
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7077

Total number of triples: 43.